New insights into the effect of amorolfine nail lacquer. by Flagothier, Caroline et al.
New insights into the effect of amorolfine nail lacquer
C. Flagothier, C. Pie´rard-Franchimont and G. E. Pie´rard
Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium
Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses
often remains uncertain. Several factors account for treatment failure, of which
the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The
taxonomic nature and ungual location of the fungus cannot be neglected, besides the
type of nail and its growth rate. In addition, the biological cycle of the fungus and
the metabolic activity of the pathogen likely play a marked influence in drug response.
The presence of natural antimicrobial peptides in the nail is also probably a key feature
controlling the cure rates. There are many outstanding publications that cover the full
spectrum of the field. The purpose of this review is to put in perspective some facets of
activity of the topical treatment using amorolfine nail laquer. The antifungal activity of
the drug is likely less pronounced in onychomycosis than that expected from
conventional in vitro studies. However, the nail laquer formulation should reduce the
propensity to form antifungal-resistant spores and limit the risk of reinfection.
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Introduction
During the last 2 decades, the efficacy of treating
onychomycoses has been considerably improved by
the introduction of new generations of potent antifun-
gals. In general, antifungal therapy has taken a
quantum leap forward in response to the physicians
need to control the ever growing number of diagnosed
mycotic infections. At the same time, the existence of
several different treatment plans with drugs that differ
in many of their characteristics has led to disagreements
in formulating indications for their use and assessing
their clinical efficacy. Opinions have been expressed
attempting to link the overall efficacy of the drugs with
its pharmacokinetic and pharmacodynamic character-
istics. Furthermore, these parameters have themselves
sometimes been put forward as significant advantages
or disadvantages for one or another of the antifungals
compared with others.
Topical treatments are often considered to be less
efficacious than current oral treatments. However, some
topical formulations may provide effects that cannot be
achieved by other treatments. In discussing the treat-
ment of onychomycosis, it should not be forgotten that
all systemic antifungals exert only fungistatic activity in
clinical conditions. Radical elimination of the causal
microorganism from the nail does not occur fre-
quently.1, 2 In fact, if antifungals were to exert
fungicidal activity, completely destroying fungi in the
nail, the duration of treatment of toenail and fingernail
onychomycoses would be identical. However, this does
not happen in practice, and treatment plans for toenail
onychomycosis are always more prolonged compared
with those for fingernail onychomycosis. The overall
difference in duration between these treatment plans
corresponds overall to the difference in the complete
regrowth rate of nail plates on the feet and hands.
Antifungal activity of amorolfine
Amorolfine is a potent antifungal drug exhibiting a
large spectrum of in vitro activity.3, 4 However, in the
field of onychomycosis, data gained by conventional
in vitro testing5 cannot be taken at face value and
extrapolated to the in vivo situation.6 This is probably
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due to drug interference with natural compounds that
can influence fungal growth. In addition, contrasting
with the in vitro testing in culture medium, fungi in
onychomycosis utilize the nail as their sole nutrition
source. Therefore they have to change their metabolism,
activating for instance the secretion of keratinases.7 As
a result of the specific nail environment and fungal
condition, the activity of antifungals may be consider-
ably decreased in nails compared with standard in vitro
testing procedures.8
The pharmacokinetic properties of amorolfine in nails
suggest a good penetration deep into the subungual
compartment.4, 9, 10 Therapeutic results in onychomy-
cosis have been reported on several occasions.11–15 The
patient’s ability to use the treatment correctly and his/
her compliance should not be overlooked in selecting
the treatment.
Fungal adherence and invasiveness
In addition to the antifungal and nail characteristics, the
taxonomic nature and life cycle of the offending fungi are
important. Numerous types of fungal propagules (spores)
are present in the environment, some of which can be
responsible for onychomycosis. The first step in the
complex pathogenic path of onychomycosis consists of
propagule adherence to the surface of the nail or the
surrounding skin. Invasion may follow, leading to
hyphae and conidia formation, and subsequent dispersal
of propagules, thus closing the pathogenic circle.
Intact skin and nail usually prevent the penetration of
most pathogenic fungi. Contact with skin scales har-
boring the fungus is commonly an essential step in the
development of superficial fungal infections. Indeed, the
adherence of tiny infected scales or fungal propagules is
the primary mechanism of fungal transmission. Discrete
abrasion of the stratum corneum and presence of soft
keratin accumulation under the distal part or the lateral
margins of the nail plate are friendly niches for
adherence of fungal propagules. Occlusion also helps
these infectious cells to cling to the cornified structures.
As fungal cells can survive for up to 2 years in a viable
state in scales, nail fragments and hair, the original
contact with an infective fungus is therefore indirect in
many instances.
Most experimental fungal invasions of the stratum
corneum rely on abrasion of the skin surface or
occlusion before dermatophytes can be induced to
establish themselves effectively as pathogens. How-
ever, the fungal inocula must usually be far heavier
than is usually experienced in an in vivo situation. In
addition, these studies do not take into account the
facilitating or inhibitory effects of endogenous molecules
and products from other saprophytic microorganisms
already colonizing the skin. Furthermore, the importance
of carbon dioxide (CO2) cannot be neglected due to its
essential role in both the formation of fungal propagules
and also the germination of the arthroconidia, resulting
in hyphal penetration of the cornified structures. High
CO2 concentrations facilitate subsequent formation of
arthroconidia. In contrast, onychocytes and corneocytes
may contain certain soluble factors that induce arthro-
conidia germination. Amino acids from human corneo-
cytes are important in this process. Some endogenous
antimicrobial peptides exert the apposite effect and act in
the scope of innate immunity.16–21
The conidia–hyphae–conidia loop
If an infected skin scale is released in a swimming pool
or shower cubicle, attachment of the fungus to corneo-
cytes allows its activation. The state of dormancy is
broken due to increased moisture levels that lead to the
initiation of germination and penetration of the corni-
fied structures. Along the invasive fungal path, germi-
nation after propagule attachment must be rapid,
otherwise the fungus is expelled by continuous desqu-
amation, nail growth and regular body cleansing.
During the invasive hyphal phase, arthrocondiia are
eventually formed again, through asexual reproduc-
tion.1, 2, 22–24 This process involves the division of
hyphae into strings of short segments separated by
double septa. This situation represents the resting state
of an otherwise filamentous fungus. In this state of
dormancy arthroconidia can survive for very long
periods of time, protected to a large extent from harsh
environmental conditions. These cells are also less
sensitive to the vast majority of antifungals.2
At this stage, the fungal life is already approaching
full circle. Indeed, the pathogenic loop begins with the
formation of hyphae that, in turn, disarticulate into
arthroconidia, and concludes with the release of infec-
tious propagules again. This cycle lends itself to elegant
studies with antimycotics, using the corneofungimetry
bioassay performed on small strips of stratum cor-
neum.6, 25–28This model permits the study of adherence,
germination and penetration of fungi in the human
stratum corneum. The effect of topical or oral antifun-
gals can be established as well.6, 25, 27–29
Amorolfine nail lacquer and fungal adherence
The ability of fungi to attach themselves to body
surfaces is the first incident in the chain of events that
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eventually results in the requirement for antimycotic
treatment. Identifying the organism and understanding
the successive steps of its pathogenic path are important
to improve therapeutic outcome.
We performed an in vitro study using non-infected big
toenails obtained at autopsy. Samples coated or uncoa-
ted with amorolfine nail lacquer were placed in humid-
ified soil for 4 weeks. Samples were then washed,
immersed in Tween 40 and prepared for histological
examination as previously described.22, 23, 30 Control-
untreated nails showed fungal invasion in 16 of 18
(88.9%) cases. In contrast, only three of 18 (16.7%) of
the amorolfine-treated samples harbored fungal hyphae.
These findings suggest that nail adhesion and growth of
keratinophylic fungi present in soil are largely inhibited
by medicated formulation. The nail lacquer may have
inhibited fungal adhesion, and amorolfine would have
probably abated incipient hyphae production.
Waking fungal conidia from dormancy
The presence of resting conidia inside the nail plate
represents a potent reservoir little affected by antifun-
gals.2 Growth of hyphae and recurrence of onychomy-
cosis may occur from these conidia when treatment is
stopped.22 Therefore, targeting this drug-resistant pop-
ulation of cells is a key feature in onychomycosis
management. This objective is conceivable through the
use of nail lacquer formualtions, which may act to break
this state of dormancy during treatment by reducing
transonychial water loss (TOWL). The normal TOWL
ranges between 10 and 20 g m)2 h)1, and is signifi-
cantly lowered in onychomycosis.31 We found that the
level of TOWL was further abated after application of
amorolfine nail lacquer. This results from the semi-
occlusive property of the formulation that may retain
moisture in the nail plate facilitating fungal germina-
tion. The induction would result in the emergence of
fungal hyphae susceptible to the antifungal activity of
amorolfine. Thus, amorolfine formulation is well suited
for eradicating resistant arthroconidia.
Another way to circumvent this fungal life process
consists in luring the dormant fungus by boosting its
growth while on antifungal treatment. The boosted
antifungal topical treatment modality showed success
using amorolfine nail lacquer.32 This procedure is safe
when the antifungal agent has a broad spectrum of
activity and when the boosting period is limited to
1 week.32 As natural host defenses are not impaired by
treatment, the risk of systemic spread of infection is no
higher than that observed in untreated patients with
onychomycosis.
Conclusion
It is a problem familiar for all dermatologists that a
number of cases of onychomycoses can be alleviated or
improved but not cured. There is ample evidence that
some broad-spectrum antifungals including amorolfine
are effective in vitro against a wide range of fungi
responsible for onychomycoses. However, the clinical
effect in treating onychomycosis is less impressive than
expected. The reasons are multiple, depending both on
the biology of the fungus and the nature of the nail
containing a mixture of fungal growth-promoting and
fungal growth-inhibiting factors. As a rule, the resulting
overall balance between antifungal drug efficacy and the
onychomycosis condition is negative. Amorolfine does
not escape this drawback. However, topical nail laquer
formulation has some advantages over oral antifungals.
It limits the adhesion of fungal propagules on and
underneath the nail plate, thus preventing reinfection
in its initial step. It also helps in hydrating the nail plate
by semi-occlusion, thus limiting the formation and
persistence of drug-resistant fungal spores.
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